[1]MERCHANT S. The JAK2 mutation[J/OL]. Int Rev Cell Mol Biol，2021，365：117-162[2022-10-30]. https://doi.org/10.1016/bs.ircmb.2021.09.002.
[2]PERNER F，PERNER C，ERNST T，et al. Roles of JAK2 in aging，inflammation，hematopoiesis and malignant transformation[J]. Cells，2019，8（8）：854.
[3]GRINFELD J，NANGALIA J，BAXTER E J，et al. Classification and personalized prognosis in myeloproliferative neoplasms[J]. N Engl J Med，2018，379（15）：1416-1430.
[4]ARELLANO-RODRIGO E，ALVAREZ-LARRÁN A，REVERTER J C，et al. Platelet turnover，coagulation factors，and soluble markers of platelet and endothelial activation in essential thrombocythemia：relationship with thrombosis occurrence and JAK2 V617F allele burden[J]. Am J Hematol，2009，84（2）：102-108.
[5]HAUSCHNER H，BOKSTAD HOREV M，MISGAV M，et al. Platelets from calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets[J]. Am J Hematol，2020，95（4）：379-386.
[6]HULTCRANTZ M，BJÖRKHOLM M，DICKMAN P W，et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms：a population-based cohort study[J]. Ann Intern Med，2018，168（5）：317-325.
[7]POLIZIO A H，PARK E，WALSH K. Clonal hematopoiesis：connecting aging and inflammation in atherosclerosis[J]. Curr Atheroscler Rep，2023，25(3)：105-111.
[8]ARACHCHILLAGE D R，LAFFAN M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms[J]. Semin Thromb Hemost，2019，45（6）：604-611.
[9]MCMULLIN M F F，MEAD A J，ALI S，et al. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis：a British society for haematology guideline[J]. Br J Haematol，2019，184（2）：161-175.
[10]HASSELBALCH H C，ELVERS M，SCHAFER A I. The pathobiology of thrombosis，microvascular disease，and hemorrhage in the myeloproliferative neoplasms[J]. Blood，2021，137（16）：2152-2160.
[11]WEISEL J W，LITVINOV R I. Red blood cells：the forgotten player in hemostasis and thrombosis[J]. J Thromb Haemost，2019，17（2）：271-282.
[12]FIDLER T P，XUE C Y，YALCINKAYA M，et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis[J]. Nature，2021，592（7853）：296-301.
[13]TEFFERI A，BARBUI T. Polycythemia vera and essential thrombocythemia：2021 update on diagnosis，risk-stratification and management[J]. Am J Hematol，2020，95（12）：1599-1613.
[14]ZHU H，JIAN Z H，ZHONG Y，et al. Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition[J/OL]. Front Immunol，2021，12：714943[2022-10-30]. https://doi.org/10.3389/fimmu.2021.714943.
